Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis

NCT02465437 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

42

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor terminated open-label extension

Conditions

Diffuse Cutaneous Systemic Sclerosis

Interventions

DRUG: JBT-101
DRUG: Placebo
DRUG: Part B Open-Label Extension

Sponsor

Corbus Pharmaceuticals Inc.